The Scorpion Therapeutics spinoff sold rights for two EGFR inhibitors to Pierre Fabre Laboratories and is hoping to become a clinical-stage firm by 2026.

Black Diamond Therapeutics's novel EGFR inhibitor shows promise in addressing resistance mutations in NSCLC and glioblastoma.

In a recent study, researchers have uncovered the biological trigger behind the dangerous immune-related adverse events (irAEs) that occur when the ...

The authorisation comes three months after the MHRA approved Johnson & Johnson’s Lazcluze (lazertinib), which is also ...

("Kelun-Biotech", 6990.HK) today announced that results from its registrational study (OptiTROP-Lung03) evaluating sacituzumab tirumotecan (sac-TMT) versus docetaxel in patients with previously ...

In a recent study, researchers have uncovered the biological trigger behind the dangerous immune-related adverse events ...

Patients with stage II and IIIB non-small cell lung cancer (NSCLC) with an EGFR mutation had better outcomes when treated ...

The MHRA has approved aumolertinib for adult patients with non-small cell lung cancer (NSCLC), following a groundbreaking ...

Lung cancer is the malignant tumor with the highest incidence and mortality rate in the world. With the in-depth research of ...

The use of tyrosine kinase inhibitors (TKIs) in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) has not produced the same durable clinical benefits ...

The molecular diagnostics firm's Idylla EGFR Mutation Test is used to guide targeted therapies for patients with non-small cell lung cancer.